Asset Management One Co. Ltd. Lowers Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Asset Management One Co. Ltd. has reduced its holdings in Regeneron Pharmaceuticals by 2.4%, owning 60,844 shares valued at approximately $31.9 million as of the latest SEC filing.
• Regeneron's stock showed a 0.4% increase, with a current trading price of $577.95 and a market cap of $61.26 billion.
• The company reported a quarterly earnings per share (EPS) of $12.89, exceeding analysts' expectations of $8.43, alongside a total revenue of $3.68 billion.

Asset Management One Co. Ltd. lessened its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 2.4% during the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 60,844 shares of the biopharmaceutical company's stock after selling 1,494 shares during the period. Asset Management One Co. Ltd. owned 0.06% of Regeneron Pharmaceuticals worth $31,943,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in REGN. Brighton Jones LLC boosted its stake in Regeneron Pharmaceuticals by 261.8% during the fourth quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company's stock valued at $675,000 after buying an additional 686 shares during the period. GAMMA Investing LLC raised its stake in Regeneron Pharmaceuticals by 41.8% in the first quarter. GAMMA Investing LLC now owns 1,286 shares of the biopharmaceutical company's stock valued at $816,000 after purchasing an additional 379 shares in the last quarter. Oppenheimer Asset Management Inc. purchased a new stake in Regeneron Pharmaceuticals in the first quarter valued at approximately $1,246,000. Spire Wealth Management raised its stake in Regeneron Pharmaceuticals by 13.9% in the first quarter. Spire Wealth Management now owns 180 shares of the biopharmaceutical company's stock valued at $114,000 after purchasing an additional 22 shares in the last quarter. Finally, Golden State Wealth Management LLC raised its stake in Regeneron Pharmaceuticals by 265.4% in the first quarter. Golden State Wealth Management LLC now owns 95 shares of the biopharmaceutical company's stock valued at $60,000 after purchasing an additional 69 shares in the last quarter. Institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Trading Up 0.4%

REGN stock opened at $577.95 on Friday. The company has a market capitalization of $61.26 billion, a PE ratio of 14.57, a price-to-earnings-growth ratio of 1.79 and a beta of 0.31. Regeneron Pharmaceuticals, Inc. has a one year low of $476.49 and a one year high of $943.83. The company's 50 day moving average price is $576.32 and its two-hundred day moving average price is $562.58. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.72 and a current ratio of 4.60.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 EPS for the quarter, topping the consensus estimate of $8.43 by $4.46. The firm had revenue of $3.68 billion for the quarter, compared to the consensus estimate of $3.30 billion. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The business's revenue was up 3.6% compared to the same quarter last year. During the same period last year, the firm posted $11.56 earnings per share. As a group, analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, September 3rd. Shareholders of record on Monday, August 18th were paid a dividend of $0.88 per share. The ex-dividend date of this dividend was Monday, August 18th. This represents a $3.52 annualized dividend and a dividend yield of 0.6%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is 8.87%.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on REGN shares. Raymond James Financial raised shares of Regeneron Pharmaceuticals to a "moderate buy" rating in a research note on Tuesday, September 2nd. Redburn Atlantic raised shares of Regeneron Pharmaceuticals to a "strong-buy" rating in a research note on Thursday, August 14th. Argus downgraded shares of Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Monday, June 30th. Royal Bank Of Canada raised their target price on shares of Regeneron Pharmaceuticals from $688.00 to $695.00 and gave the company a "sector perform" rating in a research note on Monday, August 4th. Finally, Guggenheim raised their target price on shares of Regeneron Pharmaceuticals from $810.00 to $815.00 and gave the company a "buy" rating in a research note on Friday, August 1st. Three equities research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $802.35.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.